share_log

6-K: Gsk Delivers Continued Strong Performance and Upgrades 2024 Guidance

6-K: Gsk Delivers Continued Strong Performance and Upgrades 2024 Guidance

6-K：GSK继续保持强劲业绩并上调​​2024年业绩指引
美股SEC公告 ·  2024/08/01 00:31

Moomoo AI 已提取核心信息

GSK delivered strong Q2 2024 performance with total sales of £7.9 billion, up 13% CER, driven by broad-based growth across all business areas. Core operating profit increased 18% to £2.5 billion, reflecting continued leverage from strong sales and favorable product mix. Core EPS grew 13% to 43.4p.The company upgraded its full-year 2024 guidance, now expecting sales growth of 7-9% (previously 5-7%), core operating profit growth of 11-13% (previously 9-11%), and core EPS growth of 10-12% (previously 8-10%). The improved outlook reflects strong commercial execution and strengthening portfolio breadth.R&D progress continued with positive data from key programs, including depemokimab for severe asthma and Blenrep in multiple myeloma. The company secured regulatory approvals and filings for 10 major opportunities and reported positive data from 7 phase III trials year-to-date, reinforcing confidence in future growth potential.
GSK delivered strong Q2 2024 performance with total sales of £7.9 billion, up 13% CER, driven by broad-based growth across all business areas. Core operating profit increased 18% to £2.5 billion, reflecting continued leverage from strong sales and favorable product mix. Core EPS grew 13% to 43.4p.The company upgraded its full-year 2024 guidance, now expecting sales growth of 7-9% (previously 5-7%), core operating profit growth of 11-13% (previously 9-11%), and core EPS growth of 10-12% (previously 8-10%). The improved outlook reflects strong commercial execution and strengthening portfolio breadth.R&D progress continued with positive data from key programs, including depemokimab for severe asthma and Blenrep in multiple myeloma. The company secured regulatory approvals and filings for 10 major opportunities and reported positive data from 7 phase III trials year-to-date, reinforcing confidence in future growth potential.
GSk在2024年第二季度表现强劲，总销售额达到79亿英镑，按固定汇率上涨13%，这得益于所有业务板块的广泛增长。核心营业利润增加18%，达到25亿英镑，反映出强劲销售和有利产品组合的持续杠杆效应。核心每股收益增长13%，达到43.4便士。公司升级了2024全年指导，现在预计销售增长为7-9%（之前为5-7%），核心营业利润增长为11-13%（之前为9-11%），核心每股收益增长为10-12%（之前为8-10%）。这一改善的前景反映出强大的商业执行力和不断增强的产品组合广度。研发进展持续，关键项目的积极数据，包括用于重度哮喘的depemokimab和用于多发性骨髓瘤的Blenrep。公司获得了10个主要机会的监管批准和备案，并报告说截至目前已有7项三期临床试验获得积极数据，增强了对未来增长潜力的信心。
GSk在2024年第二季度表现强劲，总销售额达到79亿英镑，按固定汇率上涨13%，这得益于所有业务板块的广泛增长。核心营业利润增加18%，达到25亿英镑，反映出强劲销售和有利产品组合的持续杠杆效应。核心每股收益增长13%，达到43.4便士。公司升级了2024全年指导，现在预计销售增长为7-9%（之前为5-7%），核心营业利润增长为11-13%（之前为9-11%），核心每股收益增长为10-12%（之前为8-10%）。这一改善的前景反映出强大的商业执行力和不断增强的产品组合广度。研发进展持续，关键项目的积极数据，包括用于重度哮喘的depemokimab和用于多发性骨髓瘤的Blenrep。公司获得了10个主要机会的监管批准和备案，并报告说截至目前已有7项三期临床试验获得积极数据，增强了对未来增长潜力的信心。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Medicus Pharma
    MDCX
    -- 3.720
    Organon & Co
    OGN
    -- 14.890
    Scilex Holding
    SCLX
    -- 0.249
    艾伯维公司
    ABBV
    -- 209.520
    诺和诺德
    NVO
    -- 69.440
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日